“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Mumbai, February 6, 2018: Pharma Major Lupin Limited reported its financial performance for the third quarter ending December 31st, 2017. These results were taken on record by the Board of Directors at a meeting held in Mumbai today.
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited, said “The quarterly performance was muted on the back of business mix as well as forex losses. We continue to grow strong in all our markets while the US business is now starting to stabilize at the current level. Our near-term priorities are to successfully commercialize Solosec, resolve the warning letter on Goa and Indore Unit 2 and continue to evolve our complex generic pipeline while accelerating growth in our other markets.”
Consolidated unaudited financial Results – Quarter III, FY2018
Amount in Rs. m.
Income Statement highlights – Q3 FY2018
Balance Sheet highlights
North America
Lupin’s North America sales grew by 5.2% to Rs. 14,321 m. during Q3 FY2018 compared to Rs. 13,611 m. during Q2 FY2018 and decreased by 34.2% compared to Rs. 21,755 m. during Q3 FY2017; accounting for 37% of Lupin’s global sales.
India
Lupin’s India formulation sales decreased by 7.8% to Rs. 10,688 m. during Q3 FY2018 compared to Rs. 11,593 m. during Q2 FY2018 and increased by 7.8% compared to Rs. 9,912 m. during Q3 FY2017; accounting for 27% of Lupin’s global sales.
Asia-Pacific (APAC)
Lupin’s APAC sales grew by 6.0% to Rs. 6,742 m. during Q3 FY2018 compared to Rs. 6,357 m. during Q2 FY2018 and increased by 20.4% compared to Rs. 5,601 m. during Q3 FY2017; accounting for 17% of Lupin’s global sales.
Lupin’s Japan sales increased by 11.8% to JPY 9,711 m. during Q3 FY2018 compared to JPY 8,685 m. during Q2 FY2018 and increased by 34.1% compared to JPY 7,244 m. in Q3 FY2017.
Lupin’s Philippines sales decreased by 9.6% to PHP 456 m. during Q3 FY2018 compared to PHP 504 m. during Q2 FY2018 and increased by 14.3% compared to PHP 399 m. during Q3 FY2017.
Europe, Middle-East and Africa (EMEA)
Lupin’s EMEA sales decreased by 1.3% at Rs. 2,721 m during Q3 FY2018 compared to sales of Rs. 2,758 m. during Q2 FY2018 and increased by 6.5% compared to Rs. 2,555 m. during Q3 FY2017; accounting for 7% of Lupin’s global sales.
Lupin’s South Africa sales decreased by 4.6% at ZAR 257 m. during Q3 FY2018 compared to ZAR 270 m. during Q2 FY2018 and increased by 12.0% compared to ZAR 230 m. during Q3 FY2017. Lupin remains the 4th largest generic player in the South African market (IQVIA MAT December 2017).
Lupin’s Germany sales increased by 13.5% at Euro 8.7 m. during Q3 FY2018 compared to Euro 7.6 m. during Q2 FY2018 and increased by 21.0% compared to Euro 7.2 m. during Q3 FY2017.
Latin America (LATAM)
Lupin’s LATAM sales grew by 6.2% at Rs. 1,481 m. during Q3 FY2018 compared to Rs. 1,395 m. during Q2 FY2018 and grew by 26.0% as compared to Rs. 1,175 m. during Q3 FY2017; accounting for 4% of Lupin’s global sales.
Lupin’s Brazil sales decreased by 7.7% to BRL 37 m. during Q3 FY2018 compared to BRL 40 m. during Q2 FY2018 and increased by 25.9% compared to BRL 29 m. during Q3 FY2017.
Lupin’s Mexico sales increased by 12.0% to MXN 173 m. during Q3 FY2018 compared to MXN 154 m. during Q2 FY2018 and increased by 9.7% compared to MXN 157 m. during Q3 FY2017.
Global API
Global API sales increased by 1.1% at Rs. 2,680 m. during Q3 FY2018 compared to Rs. 2,650 m. during Q2 FY2018 and decreased by 0.1% to Rs. 2,684 m. during Q3 FY2017; accounting for 7% of Lupin’s global sales.
Research and Development
Revenue Expenditure on R&D during Q3 FY2018 amounted to Rs. 4,757 m., 12.2% of sales as against Rs. 4,739 m., 12.2% of sales during Q2 FY2018 and Rs. 5,682 m., 12.9% of sales during Q3 FY2017.
Lupin filed 5 ANDA and received 6 approvals from the US FDA during the quarter. Cumulative ANDA filings with the US FDA stood at 382 as of December 31st, 2017, with the company having received 231 approvals to date. The Company now has 33 First-to-Files (FTF) filings including 16 exclusive FTF opportunities. Cumulative DMF filings stands at 190 as of December 31st, 2017.
The Company filed 1 MAA and received 1 approval from the European authority during the quarter. Cumulative filings with European authorities now stands at 62 with the company having received 59 approvals to date.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 11th and 7th largest generics pharmaceutical company by market capitalization (December 31st, 2017, Bloomberg) and revenues (September 30th 2017, Bloomberg LTM) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT December 2017); 2nd largest Indian pharmaceutical company by global revenues (September 30th 2017, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in Indian Pharmaceutical Market (IQVIA MAT December 2017).
For the financial year ended 31st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Safe Harbor Statement